Carisma Therapeutics announces director resignation and appointment of Sohanya Cheng

Carisma Therapeutics Inc.

Michael Torok resigns from board effective Oct 31, 2024; cites other professional commitments, no disagreement.
Sohanya Cheng elected director effective Oct 31, 2024 as Class I director until 2027 annual meeting.
Cheng will serve on audit committee (Chair: Marella Thorell, Sanford Zweifach, Cheng).
Compensation: $40K annual cash retainer, plus committee fees, and option for 38,700 shares at Oct 31 closing price, vesting monthly over 3 years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sohanya Cheng

Director

CARM · Carisma Therapeutics Inc.

Effective: 2024-10-31
Filed: October 30, 2024, 7:59 PM ET

On October 30, 2024, the Board elected Sohanya Cheng as a director of the Company, effective October 31, 2024.

Departed

Michael Torok

Director

CARM · Carisma Therapeutics Inc.

Effective: 2024-10-31
Filed: October 30, 2024, 7:59 PM ET

On October 24, 2024, Michael Torok notified Carisma Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s board of directors (the “Board”), effective October 31, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sohanya Cheng was elected as Director at Carisma Therapeutics Inc..

Action: elected
Role: Director

Exact text from the filing

On October 30, 2024, the Board elected Sohanya Cheng as a director of the Company, effective October 31, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Torok resigned as Director at Carisma Therapeutics Inc..

Action: resigned
Role: Director

Exact text from the filing

On October 24, 2024, Michael Torok notified Carisma Therapeutics Inc. (the “Company”) of his decision to resign from the Company’s board of directors (the “Board”), effective October 31, 2024.

View on SEC.gov

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-112629

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.